The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

The least common way of discovery was via screening due to a known genetic syndrome (7%). Table 2. Mode of presentation and reason for imaging in patients found to have pheochromocytoma or ...

It is also under development for paraganglioma and pheochromocytoma as second line therapy It was also under development for the treatment of primary mediastinal large B cell lymphoma, metastatic ...

It is also under development for paraganglioma and pheochromocytoma as second line therapy It was also under development for the treatment of primary mediastinal large B cell lymphoma, metastatic ...

Results from the trial will be presented at an upcoming medical meeting. “Pheochromocytoma and paraganglioma are rare tumors that form in and around the adrenal glands, and currently, there are no ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

The 2004 WHO classification of endocrine tumors defines pheochromocytoma as a tumor arising from catecholamine-producing chromaffin cells in the adrenal medulla -- an intra-adrenal paraganglioma.

The US Food and Drug Administration (FDA) will soon decide on whether to expand the label of MSD’s Welireg (belzutifan) to include its use for the treatment of the rare cancer pheochromocytoma and ...

Background Until recently, determining penetrance required large observational cohort studies. Data from the Exome Aggregate Consortium (ExAC) allows a Bayesian approach to calculate penetrance, in ...

The presented patient had recurrent pheochromocytomas, in addition to a nonfunctioning incidentaloma; his mother has a history of multiple HNPs. Familial involvement and multiple tumors within a ...